The Cardiac TBX5 Interactome Reveals a Chromatin Remodeling Network Essential for Cardiac Septation  by Waldron, Lauren et al.
Article
The Cardiac TBX5 Interactome Reveals a Chromatin
Remodeling Network Essential for Cardiac SeptationHighlightsd Isolation and characterization of the endogenous cardiac
TBX5 interactome
d TBX5 interacts biochemically and genetically with the NuRD
repressor complex
d TBX5 represses inappropriate gene programs incompatible
with cardiac development
d Human TBX5 mutations alter the NuRD interaction and
correlate with septal defectsWaldron et al., 2016, Developmental Cell 36, 262–275
February 8, 2016 ª2016 Elsevier Inc.
http://dx.doi.org/10.1016/j.devcel.2016.01.009Authors
Lauren Waldron, Jeffrey D. Steimle,
Todd M. Greco, ..., Ileana M. Cristea,
Ivan P. Moskowitz, Frank L. Conlon
Correspondence
frank_conlon@med.unc.edu
In Brief
Waldron et al. isolate the cardiac
interactome of TBX5, revealing that this
transcription factor, implicated in
congenital heart disease (CHD) and
thought to be an activator, interacts with
NuRD to repress inappropriate gene
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Human mutations in the cardiac transcription factor
gene TBX5 cause congenital heart disease (CHD),
although the underlying mechanism is unknown.
We report characterization of the endogenous
TBX5 cardiac interactome and demonstrate that
TBX5, long considered a transcriptional activator,
interacts biochemically and genetically with the
nucleosome remodeling and deacetylase (NuRD)
repressor complex. Incompatible gene programs
are repressed by TBX5 in the developing heart.
CHD mis-sense mutations that disrupt the TBX5-
NuRD interaction cause depression of a subset of
repressed genes. Furthermore, the TBX5-NuRD
interaction is required for heart development. Phylo-
genetic analysis showed that the TBX5-NuRD inter-
action domain evolved during early diversification
of vertebrates, simultaneous with the evolution of
cardiac septation. Collectively, this work defines a
TBX5-NuRD interaction essential to cardiac develop-
ment and the evolution of the mammalian heart, and
when altered may contribute to human CHD.
INTRODUCTION
Congenital malformations, or structural birth defects, are the
leading cause of infant mortality in the United States and Europe
(Dolk et al., 2010; Heron and Tejada-Vera, 2009). Congenital
heart disease (CHD) remains the most common congenital mal-
formation, with atrial septal defects (ASD) present in 116 per
100,000 live births and ventricular septal defects (VSD) present
in 307 per 100,000 live births (Gittenberger-de Groot et al.,
2014). Holt-Oram syndrome (HOS) is an autosomal disorder
associated with cardiac septal defects and is caused by domi-
nant mutations in the T-box transcription factor Tbx5 (Basson262 Developmental Cell 36, 262–275, February 8, 2016 ª2016 Elseviet al., 1994, 1997, 1999; Cross et al., 2000; Holt and Oram,
1960; Li et al., 1997). Mice heterozygous for a null mutation in
Tbx5 display many of the phenotypic abnormalities of CHD,
while mice homozygous for a null mutation in Tbx5 die by embry-
onic day 10.5 (E10.5) due to cardiac defects (Bruneau et al.,
1999, 2001; Moskowitz et al., 2004, 2007). In addition to its
role in cardiogenesis, Tbx5 is one of the key factors essential
for cellular reprogramming of fibroblasts into induced cardio-
myocytes (Ieda et al., 2010; Qian et al., 2012).
While Tbx5 is an essential transcription factor for heart devel-
opment and reprogramming, and its disease relevance is well
established, there aremany critical unanswered questions about
the mechanism of TBX5 function. In particular, the TBX5 interac-
tome has not been defined in vivo, leaving unanswered the ques-
tion of how TBX5 interacting proteins regulate TBX5’s choice of
distinct transcriptional targets, or how these interactions func-
tion to activate and/or repress target gene transcription. It is
also not known how these events, when disrupted, contribute
to CHD. To these ends, we initiated a directed proteomic-based
approach to identify endogenous cardiac proteins that function
in physical association with TBX5.
We report the discovery that TBX5 interacts biochemically and
genetically with the transcriptional repression machinery of the
nucleosome remodeling and deacetylase (NuRD) complex to
repress inappropriate expression of gene programs in the devel-
oping heart. We have further uncovered a domain of TBX5 that
forms an a helix; we show that TBX5 mis-sense mutations asso-
ciated with septal defects in human patients map to this domain.
Furthermore, HOS patient mis-sense mutations in this domain
disrupt the TBX5-NuRD interaction and elicit mis-expression of
inappropriate gene programs that are normally repressed by
TBX5. Through phylogenetic analysis across numerous verte-
brate species, we find that the NuRD interaction domain (NID)
of TBX5, and hence the interaction of TBX5 with NuRD, evolved
during the early diversification of vertebrates, simultaneous with
the evolution of cardiac septation. Thus, the TBX5-NuRD inter-
action identified here plays a central role in both cardiac devel-
opment and human congenital heart defects, as well as the
evolution of the mammalian heart.er Inc.
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Figure 1. TBX5 Interacts with the NuRD Complex
(A) (Top) The Tbx5-Avi targeting cassette contains the biotin acceptor peptide (Avi) fused in frame to the terminal coding exon of Tbx5. Neo, neomycin resistance
gene; PGK, phosphoglycerate kinase 1 promoter; Amp, ampicillin resistance gene. Exons colored brown represent untranslated exons (50 and 30 untranslated
regions). Exons colored orange represent the T-box DNA binding domain. Exons colored green represent the nuclear localization signal. Exons colored pink
represent the activation domain. (Middle) Schematic of the Tbx5 recombined locus (Tbx5Avi-Neo) upon homologous recombination. (Bottom) Schematic of the
Tbx5 locus upon introduction of Cre (Tbx5Avi).
(B) Southern blot of positive embryonic stem cell clone confirms homologous recombination.
(C) Southern blot of F2 mice confirms removal of Neo cassette upon introduction of Cre. Samples were run on the same gel but were noncontiguous.
(D) RT-PCR analysis of Tbx5Avi/+ adult hearts demonstrates presence of Tbx5Avi mRNA.
(E) Overview of the isolation and characterization of the endogenous cardiac TBX5 interactome.
(F) TBX5 transcriptional interaction network. Network nodes, labeled with mouse gene symbols, are candidate direct or indirect TBX5 protein interactions
identified from affinity enrichment of biotinylated TBX5. Network edges represent known and/or predicted functional interactions in the STRING database. Edge
(legend continued on next page)
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RESULTS
Generation of the Tbx5Avi Allele
Past attempts to isolate endogenous T-box protein complexes
have been hampered by their relative low abundance and insol-
ubility. Therefore, we introduced an Avitag epitope into the mu-
rine Tbx5 locus via homologous recombination to generate a
Tbx5Avi allele (Figure 1). The Avitag is a small peptide tag that
is biotinylated in the presence of the bacterial enzyme BirA.
Thus, the Avitag/BirA system combines minimal structural
invasiveness with the specificity and strength of the biotin-strep-
tavidin interaction, the strongest non-covalent peptide-ligand
interaction identified to date (Bayer and Wilchek, 1980; Maine
et al., 2010; Roesli et al., 2006; van Werven and Timmers,
2006; Wang et al., 2006); Tbx5Avimice were mated to mice ubiq-
uitously expressing BirA (Rosa26BirA) (Driegen et al., 2005). The
Tbx5Avi;Rosa26BirA compound homozygous mice show no overt
phenotype, have no cardiac phenotype, and are fertile. Thus, the
Avitag appears to have no effect on TBX5 activity, and expres-
sion of biotinylated TBX5Avi is not deleterious to embryonic
development.
Isolation and Characterization of the Endogenous TBX5
Interactome
To define the TBX5 cardiac interactome, we performed mass
spectrometry (MS) analysis of affinity-purified TBX5 complexes
from Tbx5Avi/Avi; Rosa26BirA/BirA cardiac nuclei (Figure 1E). We
used an unbiased gene ontology-based bioinformatics classifi-
cation to screen the functions of proteins associated with
TBX5 at a statistical relevance versus Tbx5Avi/Avi alone (no
BirA) and Rosa26BirA/BirA alone. This analysis defined a subset
of 58 candidate interactions (Table S1). We analyzed these can-
didates by functional network analysis; drawing upon the
STRING database of protein-protein interactions, 40 out of the
58 candidates were assigned to a single interconnected network
(Figures 1F and S1A).
TBX5 Interacts with Components of the NuRD Complex
In Vivo
Analysis of the TBX5 interaction network identified the heterodi-
meric FACT (facilitates chromatin transcription) complex and
several members of the TFIID (transcription initiation factor)
complex, both of which play roles in RNA Pol II-dependent
gene transcription (Berk, 1999; Saunders et al., 2003) (Figure 1F).
TBX5 has been long considered to be a cardiac transcriptional
activator. Surprisingly, in our analysis we identified TBX5 in
association with multiple components of the NuRD chromatin-
modifying complex (Figures 1F and 1G), which in most instances
functions to repress gene transcription (Wade et al., 1998;
Xue et al., 1998). We find TBX5 in association with six compo-
nents of the NuRD transcriptional repression complex: CHD4,
MTA1, RBBP4, GATAD2a, GATAD2b, and HDAC2. All the
components required for a functional NuRD complex were iden-
tified in association with TBX5, as CHD3 commonly acts in athickness reflects the combined STRING evidence score for each binary relation
scriptional complexes within the network are highlighted in red dashed boxes.
(G) Affinity isolation of endogenous TBX5Avi from 4-week cardiac nuclei confirms
(H) Affinity isolation of TBX5 from E9.5 hearts further confirms interaction of TBX
264 Developmental Cell 36, 262–275, February 8, 2016 ª2016 Elsevimutually exclusive manner with CHD4, RBBP7 and RBBP4 act
redundantly, and an additional component of the NuRD com-
plex, MBD3, has been suggested to be dispensable for tran-
scription factor recruitment (e.g., by hunchback; Kehle et al.,
1998). We confirmed the interaction of TBX5 with multiple mem-
bers of the NuRD complex in adult cardiac nuclear extracts
(Figure 1G).
As TBX5 has been shown to be required for cardiogenesis at
E9.5 (Bruneau et al., 2001), we established expression of com-
ponents of the NuRD complex in cardiac tissue at E9.5. We
found that members of the NuRD complex are strongly ex-
pressed in the heart at this stage by RT-PCR (Figure S1B). We
further demonstrate that endogenous TBX5 (untagged TBX5) in-
teracts with CHD4 at E9.5 (Figure 1H).
TBX5 and MTA1 and Cardiac Septation
To assess whether the TBX5-NuRD complex interaction was
physiologically relevant, we analyzed mutant alleles of Tbx5
and a central component of the NuRD complex, Mta1, for a ge-
netic interaction (Figures 2 and S2). At E13.5,Mta1+/mice have
no apparent cardiac defects (Figure 2C). Tbx5+/ mice exhibit
partially penetrant cardiac defects as previously described,
including ASD, VSD, and complete common atrioventricular ca-
nal (CCAVC), which includes both ASD and VSD components
(Figure 2D) (Baban et al., 2014; Basson et al., 1994, 1999; Ben-
son et al., 1996; Bruneau et al., 1999, 2001; McDermott et al.,
2005). Tbx5+/; Mta1+/ heterozygous null embryos all demon-
strated septal defects (19/19), a higher frequency of septal de-
fects than either single heterozygote alone (0/14 for Mta1+/
and 12/16 for Tbx5+/) (p = 7.1 3 109 versus wild-type and
p = 0.035 versus Tbx5+/) (Figures 2E–2J). Furthermore,
Mta1/ hearts also do not have septal defects at this stage (Fig-
ure S3). We observed no change in the left ventricular chamber
width or left ventricular wall thickness (Figures S2D and S2E)
or inferior or superior cushion size (Figures 2F–2I). To rule out a
developmental delay in septation in the Tbx5+/;Mta1+/ hetero-
zygous null embryos, we examined Tbx5+/; Mta1+/ heterozy-
gous null embryos at E14.5 and consistently observed CCAVCs
at this time point (Figures S2F and S2G). These results demon-
strate a genetic interaction between Tbx5 and Mta1 in intracar-
diac septation, providing genetic evidence for a role for the
TBX5-NuRD interaction.
TBX5 Binds to the Same Consensus DNA Site in
Activated and Repressed Target Genes
The finding that TBX5 and NuRD complex components interact
biochemically and genetically led us to hypothesize that TBX5
can function to repress aberrant gene expression in the
developing heart. To test this hypothesis, we performed RNA-
sequencing analysis and identified genes significantly downre-
gulated and significantly upregulated in Tbx5 null versus wild-
type heart tissue (Figure 3, Table S2). To determine which genes
were direct targets of TBX5, we overlaid our dataset with that of a
TBX5 chromatin immunoprecipitation sequencing (ChIP-seq)ship. Thicker edges represent increased interaction evidence. Selected tran-
interaction of TBX5 with endogenous components of the NuRD complex.
5 with the NuRD component CHD4 in the embryonic heart.
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Figure 2. TBX5 and the NuRD Complex
Genetically Interact
(A–E) Histology (H&E) of embryonic hearts in
transverse section at E13.5. (A) Low magnification
of a wild-type heart. High magnification of (B) wild-
type, (C) Mta1+/, (D) Tbx5+/, and, (E) Tbx5+/;
Mta1+/hearts. Tbx5+/; Mta1+/hearts exhibited
cardiac septal defects including ASD, VSD, and
CCAVC (asterisk).
(F–I) Histology at E13.5 through a single Tbx5+/;
Mta1+/ heart from inferior to superior revealing
ASD (G) (black asterisk) and VSD (red asterisk)
(H and I) components of CCAVC.
(J) Quantification of cardiac defects observed in
each genotype. Fisher’s exact test showed that
Tbx5+/; Mta1+/ mice demonstrated significantly
more septal defects than either wild-type or
Tbx5+/ mice. as, atrial septum; ivs, interventric-
ular septum; la, left atrium; lv, left ventricle; ra, right
atrium; rv, right ventricle.dataset (He et al., 2011) and observed that TBX5 activates and
represses sets of genes that fall into distinct categories (Figures
3A–3C). This finding raises the possibility that TBX5 may distin-
guish activated versus repressed target genes by binding to dis-
similar DNA sequences in their regulatory elements. To address
this possibility, we performed bioinformatics analysis on a large
scale. From our ChIP-seq data, 71,624 TBX5 peak regions were
identified by enrichment of signal using MACS2 (Zhang et al.,
2008). These peak regions demonstrated a significant associa-
tion with genes that were differentially regulated between Tbx5
wild-type and Tbx5/ hearts.
Given that a large number of peaks can skew results in gene-
association analyses, we varied the number of analyzed peaks
from 10,000 to 70,000 in increments of 10,000. In everyDevelopmental Cell 36, 262–275instance, TBX5 was significantly associ-
ated with differentially expressed genes
(data not shown). We selected the top
40,000 peaks for subsequent analyses
since the inclusion of additional peaks
minimally increased the number of asso-
ciated genes (data not shown). We
identified an association between TBX5
and 82% of genes differentially ex-
pressed between Tbx5 wild-type and
Tbx5/hearts (2,988 of 3,634, Fig-
ure 3A). Of these genes, about half
were activated and half were repressed
by TBX5. Both groups demonstrated a
statistically significant enrichment in
TBX5 binding sites in the TBX5 ChIP
peak regions (activated p = 4.88 3
10141, repressed p = 1.29 3 10142,
Kolmogorov-Smirnov test, Figure 3B).
Genes repressed by TBX5 were en-
riched in pathways involved in cancer
as well as cardiac diseases, while genes
activated by TBX5 were enriched in
pathways involved in cell cycle andDNA replication, a known function of TBX5 (Figure 3C) (Hatcher
et al., 2001; Goetz et al., 2006).
TBX5 Acts to Directly Repress Inappropriate Expression
of Genes in Cardiac Tissue
To validate the genes putatively repressed by TBX5, we rank or-
dered our list of repressed genes based on relative change in
expression between wild-type and Tbx5/ hearts and the num-
ber of reads from the ChIP-seq dataset (Table S3). From this
rank-ordered list, we cloned the top 15 of the ChIP peak
sequence elements from 14 genes and performed transcrip-
tional assays (Figures 4 and S4). Of the candidate genes tested,
11 were repressed by TBX5. This set of genes could be divided
into two categories: Casz1, Fgf11, Gad1, Kcne3, Kctd16, Klf4,, February 8, 2016 ª2016 Elsevier Inc. 265
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Figure 3. Analysis of TBX5 Binding Motifs in Activated versus Repressed Genes
(A) Schematic overlay between TBX5 peaks (He et al., 2011) and differentially expressed genes between wild-type and Tbx5 null heart tissue. 2,988 genes are
differentially expressed and associated with a TBX5 peak. Inset shows number of up- and downregulated genes.
(B) Activating/repressive function prediction of TBX5 peaks. Red and purple lines represent up-and downregulated genes. Black dashed line represents
background (static genes). Genes are ranked from high to low based on their regulatory potential score (RPS) determined by BETA. p values represent signif-
icance of up- or downregulated group relative to background (static genes) by Kolmogorov-Smirnov test.
(C) KEGG pathway enrichment of downregulated genes associated with TBX5 binding ranked by –log10(p value).
(D) TBX5 consensus motif (top) and top motif from de novo identification (bottom), and its presence at ChIP-seq peaks associated with activated or repressed
genes.Nxph4, Plekha2, and Sncb are expressed in neural lineages
(Diez-Roux et al., 2011; Dorr et al., 2015; Liu et al., 2011; Metz
et al., 2011; Smallwood et al., 1996; Sopher et al., 2001; Trifonov
et al., 2014; Wang et al., 2014), while Casz1, Col20a1, Fgf11,
Gad1, Klf4, Mef2b, and Plekha2 are expressed in a divergent
subset of cancers (Costantini et al., 2009; Evans and Liu, 2008;
Hu et al., 2015; Huang et al., 2013; Kimura et al., 2013; Ying
et al., 2013). Altogether, these data suggest that TBX5 function
is essential for in vivo transcriptional repression and prevention266 Developmental Cell 36, 262–275, February 8, 2016 ª2016 Elseviof ectopic expression of inappropriate gene programs in the
heart.
TBX5 InteractionwithCHD4DoesNot Require Either the
CHD4 Chromo Domains or the Phd Domains
CHD4 is a highly conserved protein that serves as the central
catalytic core component of the NuRD complex (Denslow and
Wade, 2007). Studies across plants and animals have shown
that CHD4 functions through interaction with DNA bindinger Inc.
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Figure 4. TBX5 Functions to Represses Mis-expression of Genes in Cardiac Tissue
(A) Summary of fold change (RNA sequencing) and ChIP-seq peak values of the 15 top rank-ordered genes.
(B–L) Gene reporter elements cloned from potential TBX5 targets in the presence or absence of TBX5. Transcriptional assays of target genes show that TBX5 acts
as a transcriptional repressor in 11 of 15 elements tested (additional data in Figure S4). Genes defined as neural are shown in red, expressed in cancer as blue, or
both as purple. Graphs are plotted as themean luciferase value ± SEM. Student’s two-tailed t test was used to perform statistical analysis. *p < 0.05, ***p < 0.001.proteins by its pair of chromo domains. In addition, CHD4
also contains a tandem set of Phd (plant homology domains)
and an ATPase cassette (Denslow and Wade, 2007). To
gain insight into the mechanisms of TBX5-NuRD mediated
repression, we mapped the protein interaction domains of
TBX5 and CHD4 (Figures 5A–5F). Streptavidin pulldown of
TBX5 complexes demonstrated that an N-terminal human
CHD4 region containing the pair of Phd domains and the pair
of chromo domains was required for interaction with mouse
TBX5 (Figures 5A and 5C). Surprisingly, we found that CHD4
deletions of either the Phd domains or the chromo domains still
interact with TBX5 (Figure 5D), implying that TBX5 interacts withDevelopa previously undefined set of residues in the amino-terminal
portion of CHD4.
TBX5 Interacts with the NuRD Complex through a
Coil-a-Helix Domain
In vitro-based approaches have led to the identification of a
number of proteins that interact with TBX5 through two regions
of TBX5; one in the amino-terminal portion of the protein
including the most amino-terminal portion of the T-box DNA
binding domain (Brown et al., 2005; Garg et al., 2003; Ghosh
et al., 2009; Hiroi et al., 2001; Wang et al., 2011) and a
second in the C terminus of TBX5 containing a putative nuclearmental Cell 36, 262–275, February 8, 2016 ª2016 Elsevier Inc. 267
localization signal (Krause et al., 2004; Murakami et al., 2005). To
determine whether TBX5 associates with the NuRD complex
through these regions, we mapped the residues of TBX5 that
were essential for interaction with CHD4. From these studies
we found that a region C-terminal to the T-box was necessary
and sufficient for interaction with CHD4 (amino acids 238–340)
(Figures 5B, 5E, and 5F). A conserved function for this region is
supported by our observation that the minimal region of TBX5
that interacts with CHD4 is highly conserved across 48 TBX5
orthologs (Figure 5H).
Since the region of TBX5 that interacts with CHD4 has not
been included in TBX5 crystal structural analysis (Stirnimann
et al., 2010), we sought to determine whether the region of
TBX5 that interacted with CHD4 represented a true TBX5 struc-
tural domain. We therefore conducted molecular 3D structural
modeling of the entire TBX5 protein as well as the minimal region
of TBX5, which we showed interacted with CHD4. Results from
these analyses revealed that TBX5 residues 255–264 are highly
predicted to form a small coil-to-a-helix region (Figures 5I and
5J). We have termed this structural-functional region of TBX5
the NID (TBX5NID) (Figure 5G).
The TBX5-NuRD Interaction Domain Is Essential for
Cardiac Development and Function in Humans
Having demonstrated TBX5 and the NuRD complex genetically
and biochemically interact, and having established that TBX5NID
represents a true structural-functional domain, we next deter-
mined whether the interaction between TBX5 and the NuRD
complex is essential for TBX5 function. For these studies we un-
dertook a CHD patient-driven approach based on the observa-
tions that the vast majority of molecularly characterized TBX5
mutations associated with CHD are mis-sense mutations within
the coding region of TBX5. Most of the CHD-associated muta-
tions are located within the TBX5 T-box causing either a loss
of DNA binding or degradation by non-sense-mediated decay
(Fan et al., 2003a, 2003b; Mori and Bruneau, 2004). However,
in addition there exists a subset of CHD-associated mutations
that lie in the C terminus of TBX5, outside the T-box; the resulting
mutant forms of TBX5 are stable, nuclear localized, and bind
DNA. The molecular basis for these CHD-associated mutations
has until now been unknown.
Multiple mis-sense mutations that correspond to TBX5-
associated CHD in the C-terminal region of TBX5 that fall
within the TBX5NID, including TBX5S252I, TBX5S261C, TBX5V263M,
TBX5K266R, and TBX5Q292R (Heinritz et al., 2005) (Figure 5G). We
investigated the physical location of these TBX5 amino acids on
the predicted NID structural domain and observed that the amino
acidsalignalongasingle interactionsurfaceof theTBX5NIDahelix
(Figures 5I and 5J). We hypothesized the CHD mis-sense muta-
tions in the TBX5NID disrupt the TBX5-CHD4 interaction.
We tested the hypothesis that TBX5 mis-sense mutations in
the TBX5NID alter the TBX5-NuRD association. Three single
mis-sense mutations within the TBX5NID (TBX5S261C, TBX5V263M,
and TBX5K266R) each abolished the interaction between TBX5
and both CHD4 andMTA1, and an additional two other CHD sin-
gle mis-sense mutations (TBX5S252I and TBX5Q292R) reduced the
interactions (Figure 5K). These results suggest that disruption of
the TBX5-NuRD complex in vivo causes cardiac abnormalities
associated with HOS.268 Developmental Cell 36, 262–275, February 8, 2016 ª2016 ElseviTBX5 Can Repress Target Genes in a NuRD-Dependent
Manner
Having demonstrated that the TBX5-NuRD interaction is disrup-
ted by CHD-associated mutations in the NID, we queried
whether repression of TBX5 target genes was NuRD dependent.
We performed transcriptional assays and observed that, of
the 11 validated targets repressed by TBX5, Kctd16 and
Mef2b fail to be repressed by TBX5 containing the CHD-associ-
ated mutation TBX5S261C (Figures 6A, 6B, and S5). Furthermore,
TBX5S261C failed to repress transcription of multiple elements of
the Mef2b gene (Figures 6B–6D). In addition, we were able to
ChIP CHD4 in the presence of TBX5 to these elements (Figures
6E and 6F). Taken together, these results imply that the TBX5-
NuRD complex is required to repress inappropriate gene expres-
sion in the heart and further suggest that a subset of CHD
mutants leads to the mis-expression of genes, including
Mef2b, in the developing heart.
The TBX5-NuRD Interaction Arose Concomitantly with
the Evolution of Cardiac Septation
Phylogenetic analysis of 48 TBX5 orthologs demonstrated com-
plete conservation of the TBX5NID amino acids mutated in TBX5-
associated CHD in animals with a septated heart (TBX5S261,
TBX5V263, TBX5K266) (e.g. Xenopus to human) (Figure 7). In
contrast, orthologs of TBX5 in vertebrates that lack a septated
heart (e.g. zebrafish) have an amino acid substitution present in
human CHD patients, and furthermore, this substitution ablates
the TBX5-NuRD interaction (Figure 5K). We hypothesized that
theXenopus ortholog of Tbx5would interact with theNuRDcom-
plex, but a Xenopus Tbx5 ortholog with zebrafish NID amino acid
substitutions would fail to interact with the NuRD complex. To
test this hypothesis, we generated the K266R mutation in the
Xenopus ortholog of Tbx5 (xTbx5K266R). We observed that while
mouse TBX5 (mTBX5) and xTbx5 interact with the NuRD com-
plex, xTbx5K266R has a disrupted interaction with CHD4 (Fig-
ure 7B). Thus, our data suggested that the TBX5-NuRD interac-
tion arose coincidentally with the evolution of cardiac septation
and is an essential component of an evolutionarily conserved
mechanism for cardiac septum formation.
DISCUSSION
Here we report the isolation and characterization of the in vivo
TBX5 interactome. For more than 20 years, studies have defined
TBX5 as an activator of transcription. However, our analysis
demonstrates that TBX5 interacts biochemically and genetically
with the transcriptional repression machinery of the NuRD com-
plex. We further report that TBX5 acts to repress inappropriate
gene programs in cardiac tissue. We observed that only a subset
of TBX5-repressed target genes failed to be repressed by the
mutation of the TBX5-NuRD interacting domain (e.g. HOS muta-
tion TBX5S261C; Figures 6A–6D and S5) implying that TBX5-
mediated repression occurs in both a NuRD-dependent and
NuRD-independent manner. We favor a model by which TBX5
regulates growth and differentiation of cardiomyocytes, in part
through the repression of alternate lineage-specific gene regula-
tory networks.
To date, all other predicted TBX5 interactions have been iden-
tified through in vitro studies, such as GST pulldowns in bacterialer Inc.
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Figure 6. Congenital Heart Disease-Associ-
atedMutations of TBX5Disrupt TBX5-NuRD
Complex Activity
(A–D) Transcription of the regulatory regions of
TBX5 target genes in response to wild-type TBX5
(second column) or TBX5S261C (third column).
Additional gene targets are shown in Figure S5
(n = 9 per transcriptional assay). Graphs are
plotted as the mean luciferase value ± SEM. Stu-
dent’s two-tailed t test was used to perform sta-
tistical analysis. ***p < 0.001.
(E) Schematic of ChIP primer location on Kctd16
element. The T-box binding element (asterisk) is
noted.
(F) ChIP of CHD4 from cells co-transfected with
Kctd16-Luciferase in the presence or absence of
TBX5.or cell lysates or yeast two-hybrid approaches (Brown et al.,
2005; Garg et al., 2003; Ghosh et al., 2009; Hiroi et al., 2001;
Wang et al., 2011; Krause et al., 2004; Murakami et al., 2005).
In our study we isolated and characterized the endogenous
TBX5 interactome from cardiac tissue under physiological
conditions. This in vivo isolation is highly significant given that
mutations in T-box genes are causative for more than 30 human
diseases. Although we found no evidence for an interaction
with proteins previously identified as being associated with
TBX5 (BRG1, NKX2.5, GATA4, TBX20, Myocardin, TAZ, and
BAF60C), it remains possible that these proteins interact with
TBX5 at time points of cardiac development different from those
we analyzed, or that theywere not identified in our study for tech-
nical reasons (e.g. distinct lysis buffer conditions for different
studies). Regarding the latter point, we note that if we slightlyFigure 5. Congenital Heart Disease-Associated Mutations of TBX5 Disrupt TBX5-NuRD Comp
(A) Schematic of CHD4 deletion constructs. Phd, plant homeodomain. CHD4 FL = amino acids (aa) 1–1937, CH
FL = aa 1–518, TBX5 N = aa 1–237, TBX5 C = aa 238–518.
(B) Schematic of TBX5 deletion constructs. NLS, nuclear localization signal; AD, activation domain.
(C and D) Affinity isolation of full-length TBX5-Avi-V5 with GFP-tagged CHD4 deletions reveals that CHD4 inte
CHD4, but that the Phd and chromo domains are not individually required for the TBX5-CHD4 interaction.
(E and F) Affinity isolation of CHD4with a TBX5-Avi-V5 deletion series demonstrates TBX5 sequences aa 238–3
with CHD4. This region has been termed the NuRD interaction domain (NID).
(G) Schematic of human TBX5 protein showing location of a subset of CHD-associated mis-sense mutation
(H) Sequence alignment of the TBX5NID from 48 TBX5 orthologs. Height of letters is relative conservation at
(I) Structural prediction of the TBX5NID shows the TBX5NID is composed of a coil region followed by an a he
(J) CHD-associated mis-sense mutations align along a single surface of the a helix and are predicted to d
residues TBX5S261, TBX5V263, and TBX5K266 are shown in dark blue).
(K) Immunoisolation of V5-tagged CHD-associated mis-sense mutations of TBX5 probed for CHD4 and MTA
270 Developmental Cell 36, 262–275, February 8, 2016 ª2016 Elsevier Inc.relax the statistical cutoffs, BRG1
(SMARCA4) (Takeuchi et al., 2011) does
appear to be in complex with TBX5.
TBX5 and Cardiac Septation
Our data suggest the TBX5-NuRD inter-
action arose coincidentally with cardiac
septation. This hypothesis is further sup-
ported by our observations that Tbx5+/;
Mta1+/ compound heterozygous mice
have a higher frequency of cardiac septal
defects than either single heterozygotealone (Figure 2J). Atrioventricular septal defects have been re-
ported in 18 HOS patients, and ten have been characterized to
date (Baban et al., 2014). Of these, six of the mutations lead to
the introduction of a stop codon before the TBX5NID, and one
mis-sense mutation maps within the TBX5NID and ablates the
TBX5-NuRD interaction (Figure 5K). Thus, we find a correlation
between the phenotype of patients displaying intracardiac septal
defects and the specific genotype of TBX5 patient mutations that
causes absent or altered TBX5NID.
Conclusions
Our studies demonstrate that a proteomic-based approach
coupled with protein modeling provides a powerful predictive
strategy in prioritizing patient mutations. This type of approach
should be broadly applicable to the analysis of proteinlex Interaction and Activity
D4N = aa 1–758, CHD4C = aa 1,183–1,937, TBX5
racts with TBX5 via sequences in the N terminus of
40 are both necessary and sufficient for interaction
s. NID, NuRD-interacting domain (aa 238–340).
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Figure 7. The TBX5-NuRD Interaction Evolved Concurrently with Cardiac Septation
(A) Phylogenetic comparison of TBX5 orthologs with bootstrap values. Dark-green brackets represent animals with a septated heart. Light-green brackets
represent animals without a septated heart. Sequences of core amino acid residues required for the TBX5-NuRD interaction are shown to the right. Amino acid
residues mutated in TBX5-associated CHD are in bold, and a K/R substitution from fish to frog is highlighted in pink.
(B) Immunoisolation of V5-tagged TBX5 orthologs probed for CHD4.complexes in any cell or tissue type. The power of such an
approach is underscored by recent high-throughput sequencing
studies that have led to the identification of a vast number of so-
matic mutations in coding regions of potential disease-causing
genes. Exploiting such large datasets has proved problematic
because it has not been possible to determine which mutations
are naturally occurring, non-disease-associated variants and
which are disease-causing. Results presented here demonstrate
a proteomic modeling-based strategy that can serve to prioritize
mis-sense mutations and, therefore, correlate disease-associ-
ated phenotypes with specific mutations.
EXPERIMENTAL PROCEDURES
Generation of Tbx5Avi Mice
The targeting construct to create Tbx5Aviwas created in collaboration with the
UNC Animal Models Core and the UNC BAC Core (Chapel Hill). In brief, the
biotin acceptor peptide (Avi) targeting cassette was inserted in frame to the ter-
minal exon of the Tbx5 gene. Targeted ES cells were selected and introducedDevelopintoB6mouseblastocysts. High-chimeramaleswerematedwithB6 females to
produce F1 heterozygotes (Tbx5Avi-Neo/+). Incorporation of the Tbx5Avi
construct was confirmed by PCR and southern analysis (Figure 1B), and the
presence of Tbx5Avi mRNA confirmed by RT-PCR (Figure 1D). F1 heterozy-
gotes were crossed with Sox2-Cre mice (Hayashi et al., 2002) to remove the
neomycin cassette in the F2 generation (Figure 1C). F2 compound heterozy-
gous mice were intercrossed to remove the Sox2-Cre allele and establish
Tbx5Avi/Avi homozygous lines. Tbx5Avi/Avi mice were crossed to Rosa26BirA
mice (JAX) (Driegen et al., 2005). Resultant progenywere intercrossed to obtain
compound homozygotes. Genotyping was performed by PCR. Genotyping
primers are listed in Supplemental Experimental Procedures. Southern probe
was designed to Tbx5 intron 8. Genomic DNA was digested with EcoRV or
BamHI. Animal care and animal experiments were conducted in accordance
with theAnimal CareCommittee at theUniversity of NorthCarolina, Chapel Hill.
Preparation of Cardiac Nuclei
Frozen hearts from 4-week-old Tbx5Avi/Avi; Rosa26BirA/BirA (n = 3, two repli-
cates) and Tbx5Avi/Avi or Rosa26BirA/BirA control mice (n = 3, one replicate per
genotype) were homogenized using a mortar and pestle in liquid nitrogen.
Nuclei were prepared as previously described (Franklin et al., 2011) and
snap-frozen in liquid N2.mental Cell 36, 262–275, February 8, 2016 ª2016 Elsevier Inc. 271
Solubilization of Protein Complexes
Plasmids were transfected into HEK293 cells, harvested, and lysed as previ-
ously described (Kaltenbrun et al., 2013). E9.5 hearts were harvested in PBS
and lysed as described (Kaltenbrun et al., 2013). Cells and nuclear pellets
were resuspended in lysis buffer (20 mM K-HEPES [pH 7.4], 0.11 M KOAc,
2 mM MgCl2, 0.1% Tween 20, 1 mM ZnCl2, 1 mM CaCl2, 0.5% Triton X-100,
500 mM NaCl, 13 protease inhibitors [Roche], and 13 phosphatase inhibitors
[Sigma]), optimized for TBX5 complexes. Nuclei were homogenized using a
Polytron (Kinematica), and processed for affinity purification or immunoprecip-
itation as described by Kaltenbrun et al. (2013).
Conjugation of Magnetic Beads and Affinity Purification
Conjugation of V5 (Invitrogen R960-CUS) or TBX5 (Aviva ARP33403-P050)
antibody to magnetic beads (Invitrogen), and immunoisolation of protein com-
plexes was performed as described previously (Cristea et al., 2005; Kaltenbrun
et al., 2013), with the following modifications for streptavidin-coated beads.
Affinity purifications performed using streptavidin-conjugated Dynabeads
(Invitrogen) by slow rocking at room temperature for 30 min. The isolated pro-
tein complex was eluted for 20 min at 95C in 40 ml of 80 mM NaOAc (pH 9.0)
and 95% formamide. Western blots were probed with mouse anti-V5 (1:5,000;
Invitrogen R960-CUS), rabbit anti-CHD4 (1:500; Active Motif 39,289), mouse
anti-HDAC2 (1:1,000; Abcam Ab51832), rabbit anti-MTA1 (1:5,000; Bethyl
A300-280A), rabbit anti-TBX5 (1:1,000; Aviva ARP33403-P050, using light
chain-specific rabbit secondary), goat anti-TBX5 (1:500; Santa Cruz SC-
17866), and mouse anti-GFP (1:10,000; Clontech 63,281).
Mass Spectrometry
Isolated protein complexeswere analyzed byMS as previously described (Kal-
tenbrun et al., 2013). In brief, tandem MS (MS/MS) spectra were extracted by
Proteome Discoverer (Thermo Fisher Scientific), and all MS/MS spectra were
analyzed with SEQUEST (Thermo Fisher Scientific; version 1.2.0.208), set up
to search the human and mouse UniProt-SwissProt protein sequence
database, assuming digestion pattern with trypsin. Scaffold (version Scaffold_
3_00_06; Proteome Software) was used to validate MS/MS-based peptide
and protein identifications. Peptide sequences were deemed a match if they
could be established at >95.0% probability as specified by the Peptide
Prophet algorithm (Keller et al., 2002). In turn, protein identifications were
deemed a match if they could be established at >99.0% probability by the
ProteinProphet algorithm and have at least two sequenced peptides. Protein
identifications and associated spectral counts were exported to Excel for
further data processing.
Interaction Bioinformatics Analysis
Protein identifications were filtered to exclude non-specific associations. Pro-
teins were retained as specific candidates if they (1) had at least two spectral
counts in both Tbx5Avi/Avi; Rosa26BirA/BirA replicates with at least four spectral
counts in one replicate, and (2) were uniquely identified or had at least a 2.5-
fold spectral count enrichment in the Tbx5Avi/Avi; Rosa26BirA/BirA condition
versus the controls. Candidates were assigned gene ontology classification
using the UniProt GOA annotations from within the Cytoscape (v3.2) platform
(Cline et al., 2007). Gene symbols were submitted to the Web-based STRING
database (Franceschini et al., 2013) for interaction network analysis. Interac-
tions with a combined STRING score of >0.4 (medium confidence) were re-
tained, exported, and further visualized in Cytoscape.
RNA Extraction and RT-PCR
Adult (n = 2) hearts were cryolysed (2.5 min/cycle, 30 Hz, 20 cycles) in Trizol
(Invitrogen) and RNA extracted using Trizol, and purified on RNeasy columns
(Qiagen). cDNA synthesis was performed from 0.5 to 1 mg of RNA using
random primers and SuperScript II reverse transcriptase (Invitrogen). Expres-
sion levels assessed using GoTaq Green Master Mix (Promega) and Taq poly-
merase by GeneAmp PCR System (Applied Biosystems). PCR products were
analyzed by gel electrophoresis. RT-PCR primer sequences are provided in
Supplemental Experimental Procedures.
Transcriptional Assays
ChIP peak regions from candidate genes were amplified frommouse genomic
DNA and subcloned into the PGL3-Promoter Luciferase vector (Promega).272 Developmental Cell 36, 262–275, February 8, 2016 ª2016 ElseviPrimer sequences are listed in Supplemental Experimental Procedures.
HEK293 cells were transfected with 600 ng of total DNA in 12-well plates using
FuGene6 (Promega) and harvested 48 hr later for transcription assay, per-
formed using the Dual Reporter Assay System (Promega) according to the
manufacturer’s protocol in three biological and three technical replicates per
assay.
DNA Constructs
Generation of the Tbx5Avi targeting construct for embryonic stem cells and
generation of chimeric mice were performed by JrGang Chen (UNC BAC
Core-Chapel Hill). Tbx5-Avi-V5was generated by synthesizing an oligo encod-
ing the Avi tag (50-ggc CTG aac gac atc ttc GAG gct CAG AAA atc gaa tgg cac
gaa-30) and subcloning it into the pcDNA3.1/V5-His TOPO vector (Invitrogen).
Full-length and truncated versions of mouse Tbx5 were then subcloned into
pcDNA3.1-Avi-V5. pEF1a-BirA-V5-Neo was generously provided by Stuart
Orkin (Harvard University) (Kim et al., 2009). GFP-tagged full-length, C-termi-
nal, andN-terminal humanCHD4 constructs were generously provided by Ste-
phen Jackson (Cambridge) (Polo et al., 2010). Site-directed mutagenesis
primers are available in Supplemental Experimental Procedures.
Genetic Interaction and Histology
Tbx5fl/fl mice were generously provided by Jon and Christine Seidman (Har-
vard Medical School). The Tbx5+/ mouse has been reported (Bruneau et al.,
2001). The Mta1+/ mouse line was generated by Harold Olivey (Indiana Uni-
versity Northwest) and generously provided by Eric Svensson (Novartis Insti-
tutes for Biomedical Research). All mice are in a mixed B6/129/SvEv/CD-1
background, and experiments were performed according to a protocol re-
viewed and approved by the Institutional Animal Care and Use Committee of
the University of Chicago, in compliance with the USPublic Health Service Pol-
icy on Humane Care and Use of Laboratory Animals. E13.5 and E14.5 wild-
type, Tbx5+/, Mta1+/, and Tbx5+/;Mta1+/ embryos were dissected from
timed matings. Embryos fixed in 4% paraformaldehyde (PFA) overnight and
sent to the Human Tissue Resource Center at the University of Chicago for
paraffin embedding, sectioning, and H&E staining. Slides were imaged on a
Leica DM2500 microscope and QImaging Retiga 2000R 1394 Color Cooled
camera. Mta1/ null hearts were sectioned and prepared as previously
described (Dorr et al., 2015).
RNA Sequencing
Heart tube dissectionswere performed as described by Hoffmann et al. (2014).
In brief, E9.5 Tbx5+/+ and Tbx5/ heart tubes were dissected away from the
body nearest the myocardial reflections, and four heart tubes were pooled
to isolate sufficient RNA. Genotypes were assigned via PCR. Pools of tissue
were mechanically homogenized in TRIzol Reagent (Invitrogen) and RNA
was isolated in accordance with the manufacturer’s instructions. RNA resus-
pended in water was further purified with 500 ml of 1-butanol (four times) and
500 ml of diethyl ether (twice) (Krebs et al., 2009). Isolated RNA underwent li-
brary preparation and 51-bp single-ended RNA sequencing at the Genomics
Core Facility at The University of Chicago. Briefly, mRNA was selected using
an oligo-dT pulldown, and barcoded libraries were prepared according to
Illumina’s instructions accompanying the TruSeq RNA Sample prep kit v2
(Part# RS-122-2001). Library fragments of 275 bp (insert plus adaptor and
PCR primer sequences) were quantitated using the Agilent Bio-analyzer
2100 and pooled in equimolar amounts. The pooled libraries were sequenced
on the HiSeq2500 in Rapid Run Mode following the manufacturer’s protocols
(Invitrogen).
The raw data output from the IlluminaGenomeAnalyzer was in phred-scaled
base-64 fastq format, representing the sequence and quality scores for each
read. The single-ended 51-bp reads were filtered based on their quality scores
using the FastQC toolkit (Andrews, 2010), selecting for the 37-bp reads on the
right with a minimum quality score of 35 in 75% of the bases of the read. The
reads passing the filter were aligned to the mouse genomemm10 assembly by
TopHat (version 2.0.6) using default parameters (Kim et al., 2013). The output
SAM files were filtered for alignment sorting, and converted to BAM files using
Samtools (Li et al., 2009). Hit counts were estimated and normalized by both
the length of each transcript and the total yield of the sequencer using Cufflinks
(version 2.1.1, default parameters and ‘‘-p 2’’) (Trapnell et al., 2012). Among all
Cufflinks-reported transcript abundances, the FPKM (fragments per kilobaseer Inc.
of exon per million fragments mapped) values larger than 0.125 in all samples
were kept for the following statistical analysis. This filter guaranteed the me-
dian correlation coefficient >0.96 between any two biological replicates while
it kept65% of all transcripts, including 11,789 coding genes (Ensembl anno-
tation, mm10, April 2014 version). Differential expression between mutant
samples (n = 2) and wild-types (n = 4) was tested using Cuffdiff (v2.1.1) (Trap-
nell et al., 2012). Although Cuffdiff lacks power for designs with fewer than
three replicates per group, the low variability of the two biological replicates
in all cases (r > 0.96) guarantees the statistical power of a fold change to reveal
biologically meaningful results. All genes with an adjusted p value of less than
0.05 and absolute fold change larger than 1.57 were considered significant.
Large-Scale Bioinformatics Analysis of TBX5 Binding Sites
Differentially expressed genes were determined by q value (<0.05) and status
(‘‘OK’’). Those genes that did not meet the status threshold were given a non-
significant q value (qval = 1). TBX5 ChIP-seq FASTQ data were downloaded
from GEO (GSE21529). Tags were filtered using TagDust (Lassmann et al.,
2009) and aligned to the mouse genome (mm9) using bowtie (Langmead
et al., 2009). Peaks were called using MACS2 (Zhang et al., 2008) with default
parameters. Peaks were associated with differentially expressed genes, and
differential motif enrichment was determined using BETA (Wang et al., 2013)
with the following options: -pn 40,000 and -df 0.05 -da 1. Because BETA
uses a curated database that lacks the TBX5 motif, TBX5 peaks associated
with differentially regulated genes were also analyzed for motif enrichment us-
ing HOMER (Heinz et al., 2010). Genes associated with TBX5 regulation were
then analyzed for pathway enrichment using DAVID (Huang da et al., 2009).
The top ten (by p value) KEGG pathways are shown for both activated and
repressed genes.
Chromatin Immunoprecipitation
HEK-293 cells were transfected with the Kctd16-Luciferase construct used in
transcriptional assays, as well as wild-type TBX5 or TBX5S261C (20 mg of total
DNA) using FuGene 6 (Promega). Cells were fixed in 1%PFA for 10min at room
temperature. Ten million cells were used per ChIP. Cells were lysed in ChIP
buffer (50 mM Tris [pH 7.5], 140 mMNaCl, 1 mM EDTA, 1 mM EGTA, 0.1% so-
dium deoxycholate, 0.1% SDS), sonicated using a Branson 450d, 12 cycles,
30 s/cycle [1 s on, 0.5 s off], 30% amplitude), and spun at top speed to isolate
chromatin. Triton X-100 was added to 1%, and the chromatin was added to
CHD4-conjugated Protein G beads (Life Technologies) at 4C overnight.
ChIP was resumed using ChIP Protocol (Agilent). The ChIP primer sequence
is available in Supplemental Experimental Procedures.
TBX5 NID Modeling
Themouse TBX5 sequence was submitted to the DisProt PONDR-FIT disorder
predictor to identify disordered regions in the protein. Both the entire protein
and just the NID region were submitted to the fold recognition server HHpred
(http://toolkit.tuebingen.mpg.de/hhpred) to determine whether any suitable
templates were available for structural modeling. A small coil-to-helical region
involving residues 255–264was predicted by HHpred. This region of TBX5was
modeled based on the correspondingly small region of the structure of the
CRISPR-associated protein (PDB: 3VZI).
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